Low molecular weight heparin prophylaxis: a boon for women with history of placental mediated complications


  • Shweta Singh Department of Obstetrics & Gynaecology, V.M.M.C. & Safdarjang Hospital, New Delhi, India
  • Renuka Sinha Department of Obstetrics & Gynaecology, V.M.M.C. & Safdarjang Hospital, New Delhi, India; Department of Obstetrics & Gynaecology, Rama Medical College, Ghaziabad, Uttar Pradesh, India
  • Mayank Kaushik Department of Dermatology, MMIMSR, Ambala, India & E.S.I.C Basaidarapur, Delhi, India


Low molecular weight heparin, Preeclampsia, Abruption, Stillbirth, Fetal growth restriction


Background: Prevention of placental mediated pregnancy complication is likely the best approach to decrease maternal mortality and morbidity. Anticoagulation therapy represents a good preventive option. 

Methods: A prospective randomized case control study was conducted at Safdarjang hospital. Patients were recruited from Sept. 2011 till May 2012 and followed till delivery. Thirty cases & controls were enrolled which comprised of non- thrombophilic patients with previous history of severe preeclampsia, Fetal Growth Restriction (FGR), severe placental abruption, stillbirth after 20 weeks. Study group received LMWH according to weight subcutaneously, once daily started at < 15 weeks till 36 weeks of gestation. Maternal outcomes were observed in both groups.

Results: Incidence of stillbirth and abruption were significantly lower in study group (0 versus 3.3%, P = 0.05; and 0 versus 20%, P = 0.01). The respective incidence of severe preeclampsia and FGR were 6.6% versus 40% (P = 0.04) and 6.6% versus 30 % (P = 0.02). There was reduction of 72.7% of total adverse outcome.

Conclusions: Prophylactic LMWH before 15 weeks of gestation decreases the incidence of placental mediated complications in non thrombophilic pregnant women who had previously suffered with these complications.


Kupterminc MJ, Eldor A, Steinman N, Mary A, Bar-Am A, Jaffa A, et al. Increased frequency of the genetic thrombophilia in women with complication of pregnancy. N Engl J Med. 1999;340:9-13.

Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombosis Risk and economic assessment of thrombophilia screening (TREATS) study. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171-96.

Rodger MA. Thrombophilia and placenta mediated pregnancy complications: from the bench to bedside to policy. Thromb Res. 2009;123(Suppl 2):S100-4.

Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynaecol. 2008;112:320-4.

Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathological features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynaecol. 2001;98:1041-4.

Mousa HA, Alfirevic1 Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod. 2000;15:1830-3.

Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998;7:277-86.

Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placenta mediated complications of pregnancy in women without thrombophilia: A pilot randomized controlled trial. J Thromb Haemost. 2009;7:58-64.

Oyelese Y, Ananth CV. Placental abruption. Obstet Gynaecol. 2006;108:1095-101.

Blajchman, MA, Young, E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci. 1989;556:245-54.

Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353(9160):1258-65.

Kupferminc M, Rimon E, Many A, Maslovitz S, Lessing JB, Gamzu R. LMWH versus no treatment in women with previous severe pregnancy complications and placental finding without thrombophilia. Blood Coagul Fibrinolysis. 2001;22:123-6.

Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353(9160):1258-65.

Mello G, Parvetti E, Fatin C, Riviello C, Gensini F, Marchionni M, et al. Low Molecular Weight Heparin lowers the recurrence rate of preeclampsia and restores physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45(1):86-91.

Harenberg J, scheinder D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis. 1993;23:314-20.

Leach RE, Kilburn BA Petkova A, Romero R, Armant DR. Diminished survival of human cytotrophoblast cells exposed to hypoxia/reoxygenation injury and associated reduction of heparin-binding epidermal growth factor - like growth factor. Am J Obstet Gynaecol. 2008;198(4):471.e1-7.






Original Research Articles